Picard Medical / SynCardia to Present Webinar on the Emperor Fully Implantable Total Artificial Heart Hosted by DeviceTalks

Rhea-AI Summary

Picard Medical (NYSE American: PMI) and SynCardia will present a DeviceTalks Tuesdays webinar on Feb 3, 2026, covering the Emperor fully implantable total artificial heart.

COO Matt Schuster will review preclinical bench and acute in vivo data focusing on hemodynamic performance, robustness, physiological responsiveness, and system stability.

News Market Reaction

%

1 alert

% News Effect

$133M Market Cap

0.5x Rel. Volume

On the day this news was published, PMI declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Webinar date: February 3, 2026 Webinar time: 12:00 pm ET 52-week high: $13.68 +1 more

4 metrics

Webinar date February 3, 2026 DeviceTalks Tuesdays webcast featuring Emperor platform update

Webinar time 12:00 pm ET Scheduled live virtual webinar session

52-week high $13.68 Pre-news 52-week trading range context

52-week low $0.15 Pre-news 52-week trading range context

Market Reality Check

Price: $1.69 Vol: Volume 125,561 vs 20-day ...

low vol

$1.69 Last Close

Volume Volume 125,561 vs 20-day average 187,340 (relative volume 0.67) ahead of the webinar update. low

Technical Shares at $1.80, trading below the 200-day MA of $2.74 after a long slide from the $13.68 52-week high.

Peers on Argus

PMI fell 1.64% with light volume, while several device peers (CTKB, KIDS, LAB) a...

PMI fell 1.64% with light volume, while several device peers (CTKB, KIDS, LAB) also traded lower, but no names appeared in momentum scans and there were no same-day peer headlines, suggesting stock-specific trading rather than a coordinated sector move.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Podcast exposure	Positive	+4.8%	Podcast series launch featuring STAH and Emperor vision and market opportunity.
Jan 12	R&D collaboration	Positive	-1.2%	Hydrix development collaboration for Emperor TAH with potential 43% R&D incentives.
Jan 07	Conference meetings	Positive	+10.4%	JPM week conference attendance and investor meetings in San Francisco.
Jan 06	Product enhancement	Positive	+3.6%	Rollout of FDA-cleared CPC1 Connector Covers to enhance STAH comfort and safety.
Dec 30	Governance update	Positive	-6.4%	CEO elected to AZBio board, reinforcing regional life sciences engagement.

Pattern Detected

Recent company news, mainly communications and product updates, often saw positive price reactions, but there are notable instances of negative reactions to seemingly constructive announcements.

Recent Company History

Over the past months, PMI has highlighted communication and technology milestones, including podcast exposure for the SynCardia Total Artificial Heart and Emperor device on Jan 13, 2026 and a Hydrix development collaboration announced Jan 5, 2026. Conference participation around JPM week on Jan 12–14, 2026 and rollout of an FDA-cleared accessory from Jan 15, 2026 also featured. A CEO board election on Dec 30, 2025 showed that even positive governance news can coincide with negative price moves.

Market Pulse Summary

This announcement highlights another communication event around the Emperor fully implantable total ...

Analysis

This announcement highlights another communication event around the Emperor fully implantable total artificial heart, adding to a series of outreach efforts that include podcasts, conferences, and prior data presentations. Investors may track how preclinical and in vivo data evolve from earlier disclosures into more formal milestones. With shares trading below the $2.74 200-day MA and far under the $13.68 52-week high, the balance between technology progress and previously disclosed financing structures remains a key consideration.

Key Terms

total artificial heart, preclinical, in vivo, hemodynamic

4 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

preclinical medical

"review preclinical experience with SynCardia’s next-generation, fully implantable"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

in vivo medical

"The presentation will include bench and acute in vivo data, with emphasis"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

hemodynamic medical

"with emphasis on hemodynamic performance, robustness, physiological responsiveness"

Relating to blood flow and the forces that move it through the body, hemodynamic describes how blood pressure, volume and circulation behave in vessels and organs. Investors pay attention because changes in hemodynamics are key measures of whether a drug, device or procedure is safe and effective—think of it like plumbing and traffic: blockages or pressure spikes can signal big risks or benefits that affect a product’s regulatory approval, market adoption and reimbursement.

AI-generated analysis. Not financial advice.

TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company’s fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks.

During the session, Mr. Schuster will review preclinical experience with SynCardia’s next-generation, fully implantable total artificial heart platform, Emperor. The presentation will include bench and acute in vivo data, with emphasis on hemodynamic performance, robustness, physiological responsiveness, and system stability. The session will also feature a personal perspective from Mr. Schuster on how his multidisciplinary background and experience contributed to the development of the Emperor platform, offering insight intended to inspire innovation across the medical device community.

Details of the webinar are below:

Title: The Emperor: A Fully Implantable, Mechanically Driven Next-Generation SynCardia Total Artificial Heart
Date: February 3^rd, 2026
Time: 12:00pm ET
Host: DeviceTalks — DeviceTalks Tuesdays Webcast Series
Format: Live virtual webinar
Registration: Click here to register

The webcast will be available for download and streaming on all major platforms, including Apple Podcasts, Spotify, and Google Podcasts and available directly on DeviceTalks Tuesday’s website here.

About DeviceTalks Tuesdays

DeviceTalks Tuesdays iis a weekly webcast series designed to help MedTech professionals stay current and perform at the highest level in service of patients and customers. Organized by the DeviceTalks’ editorial team, the series brings together industry leaders, innovators, and operators for timely discussions and educational sessions tailored to medical technology companies navigating rapid change. Programming focuses on the core pillars of the DeviceTalks platform, including innovation and finance, product development, manufacturing and sourcing, regulatory reimbursement and market development, and emerging tools and technologies shaping the future of the industry. Each session is structured to fit the presenter and topic and may include keynote interviews, panel discussions, interactive presentations, and guided question and answer engagement. DeviceTalks Tuesdays unites MedTech professionals around a shared goal of continuous learning, collaboration, and improvement across the medical device ecosystem.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

When is Picard Medical (PMI) presenting the Emperor fully implantable total artificial heart webinar?

Picard Medical will present on February 3, 2026 at 12:00pm ET. According to Picard Medical, the live DeviceTalks webcast will feature preclinical bench and acute in vivo data and a personal perspective from COO Matt Schuster.

What topics will Matt Schuster cover about the Emperor platform in the PMI webinar?

Mr. Schuster will review bench and acute in vivo preclinical data emphasizing hemodynamics, robustness, responsiveness, and stability. According to Picard Medical, the presentation will highlight system performance and practical insights from his multidisciplinary experience.

How can investors and professionals register or view the Picard Medical (PMI) DeviceTalks webinar?

Registration is via the DeviceTalks Tuesdays webcast registration link for the live event. According to Picard Medical, the webcast will also be downloadable and streamable on major platforms including Apple Podcasts, Spotify, and Google Podcasts.

Will the DeviceTalks webinar include data on the Emperor total artificial heart's performance?

Yes, the webinar includes bench and acute in vivo data focused on hemodynamic performance and system stability. According to Picard Medical, those preclinical results will be reviewed to illustrate robustness and physiological responsiveness.

Who is presenting for SynCardia/Picard Medical (PMI) and what perspective will they share?

COO Matt Schuster will present and share a personal, multidisciplinary perspective on development of the Emperor platform. According to Picard Medical, he will discuss how his background informed design choices and aims to inspire medical device innovation.